AbCellera Biologics Inc. (NasdaqGS:ABCL) acquired TetraGenetics, Inc. for $62.5 million on September 10, 2021. AbCellera Biologic acquired 100% of the issued and outstanding shares of TetraGenetics in exchange for upfront cash consideration of $12.5 million adjusted for certain closing amounts; potential milestone payments up to $37.5 million based on the achievement of technical milestones, and additional development and commercial milestone payments related to successfully developed therapeutics. The Company deposited an additional $12.5 million in escrow included as part of other assets subject to release to the former shareholders of TetraGenetics upon the achievement of certain technical milestones. Latham & Watkins LLP acted as legal advisor to TetraGenetics, Inc. AbCellera Biologics Inc. (NasdaqGS:ABCL) completed the acquisition of TetraGenetics, Inc. on September 10, 2021. AbCellera Biologics Inc. acquired TetraGenetics for upfront consideration of $12.5 million in cash with the possibility of future technical milestones payable to TetraGenetics based on successful therapeutic candidates.